Our mission is to transform current cancer treatments by directly targeting tumors while minimizing toxic side effects of traditional chemotherapy.
We are addressing an urgent unmet clinical need with TEX Core, an oncology drug platform designed to treat multiple solid tumor indications.
A world first platform, TEX Core primarily uses texaphyrin as the basis for a series of conjugates designed to treat drug-sensitive and drug-resistant solid tumors.
TEX Core-developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies.
The first TEX Core oncology compound to be developed is OxaliTEX, which localizes to solid tumors including ovarian, lung and colorectal cancers.
OxaliTEX activates within cancer cells, overcoming multiple mechanisms of resistance and minimizing toxic side effects. The lead indication for OxaliTEX is ovarian cancer, the number one cause of gynecological cancer deaths globally.
Chemical Society Reviews Journal Explores How OncoTEX’s Gold-Based Compounds Can Activate the Immune System to Fight Cancer
Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX
OncoTEX Inc. appoints Chief Executive Officer
Production Underway on a New Weapon to Fight Ovarian Cancer